Compare · ABT vs UPC
ABT vs UPC
Side-by-side comparison of Abbott Laboratories (ABT) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 7951.2x UPC ($25.3M).
- ABT has hit the wire 8 times in the past 4 weeks while UPC has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for UPC).
- Company
- Abbott Laboratories
- Universe Pharmaceuticals Inc.
- Price
- $116.11-0.50%
- $5.11-8.91%
- Market cap
- $200.95B
- $25.3M
- 1M return
- +11.04%
- -
- 1Y return
- -11.76%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest UPC
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- 4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
- Chief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.